Bristol Myers’ blockbuster drug Reblozyl just flopped in a key cancer anemia trial—meaning it didn’t help enough patients ditch blood transfusions. This is a big deal since the company’s future plans hinge on expanding these meds. Analysts are side-eyeing other recent misses too. Still, Bristol Myers is trying to stay positive, saying Reblozyl did help some folks need fewer transfusions. Meanwhile, rival Disc Medicine’s stock actually jumped on the news! Pharma drama, anyone? #Health #BodyHealth #PharmaNews